Semax: how the ACTH fragment was modified for stability

Semax differs from ACTH(4 to 10) by replacing its C-terminal Arg-Trp-Gly with Pro-Gly-Pro. Comparative rat blood and serum tests report greater resistance to degradation under those conditions, but this does not establish stability in every tissue or stronger effects.

Key takeaways

• Semax is described as a synthetic peptide based on ACTH(4 to 10).
• The product description calls Semax a synthetic seven-amino-acid peptide derived from ACTH(4 to 10).
• The product description says Semax was modified for stability.
• Enzyme and serum tests report results under the conditions used in each test.
• Greater stability does not establish receptor action, safety, or clinical benefit.

How Semax differs from ACTH(4 to 10)

ACTH means adrenocorticotropic hormone. ACTH(4 to 10) names a seven-amino-acid fragment of that hormone, from position 4 through position 10.

Semax is a synthetic seven-amino-acid peptide analog, meaning a lab-made peptide based on a natural sequence but changed. The three-letter labels in the sequences are standard short forms for amino acids.

Met, Glu, His, Phe, Arg, Trp, Gly, and Pro are the standard abbreviations for methionine, glutamic acid, histidine, phenylalanine, arginine, tryptophan, glycine, and proline.

Semax is described as a modified synthetic peptide based on an ACTH fragment, rather than the unchanged fragment.

Why the Pro-Gly-Pro ending matters

Enzymes are proteins that speed up chemical reactions. Some enzymes cut peptides into smaller pieces, and the amino acids near a cut site can affect whether an enzyme recognizes that site.

In Semax, the ACTH fragment's terminal Arg-Trp-Gly is replaced with Pro-Gly-Pro. Proline's constrained ring can make nearby peptide bonds less readily recognized by some proteases, while the terminal proline changes what enzymes encounter at the chain end. This may help explain reduced cleavage in particular assays, but it is not a general shield: enzymes can still attack other sites, including the unchanged N-terminus.

The product description calls Semax modified for stability. That description does not show how the peptide behaves in a specific enzyme or serum test.

Comparative tests in rat blood and serum reported greater resistance to degradation for Semax than for ACTH(4 to 10) under the test conditions. HPLC analysis followed intact peptide and breakdown products, including progressive loss of N-terminal residues. Bestatin-sensitive aminopeptidase activity was implicated in that N-terminal breakdown route. These findings support a relative difference in those test systems; they do not establish the same breakdown rate in living tissues or account for every enzyme that may act on either peptide.

A stability description alone does not show that a peptide resists every form of breakdown or establish its effects.

The N-terminal end can still be cut

The N-terminus is the start of a peptide chain. Changes at one end of a peptide do not, by themselves, describe the other end.

N-terminal aminopeptidases are enzymes that remove amino acids from a peptide's start. Their action is a separate possible breakdown route from cuts near the changed C-terminal end.

This distinction matters when interpreting a stability test. A stability description does not show how a peptide breaks down at each end of its chain.

What enzyme and serum tests can show

In an enzyme test, researchers can expose a peptide to a chosen enzyme under set conditions. They take samples over time and measure how much intact peptide remains or which smaller fragments appear.

A fair comparison needs the same test conditions for both peptides. Temperature, acidity, enzyme amount, starting peptide amount, and test time can all affect the result.

Serum is the liquid part of blood left after clotting. Serum tests place a peptide in that liquid and track breakdown under the chosen test conditions.

A serum test can show how a peptide breaks down in that serum and test setup. It does not establish what happens in other tissues.

A half-life is the time it takes for the measured amount of a substance to fall by half. A half-life measured in a test system describes that system and does not by itself establish how long the peptide lasts elsewhere.

High-performance liquid chromatography, or HPLC, is a lab method that separates parts of a sample. Mass spectrometry measures molecular mass, which can help identify intact peptide and breakdown fragments.

Purity describes the share of measured sample signals linked to the main peptide. Content describes how much peptide is present in the sample, so a purity result alone does not give the amount present.

A certificate of analysis reports tests on a sample. The guide to reading a certificate of analysis can help explain test terms, while the laboratory testing information gives related context. Neither type of document turns a stability result into evidence of a treatment effect.

Stability is not the same as biological effect

Semax is a synthetic peptide analog based on an ACTH fragment. Sequence similarity alone does not show that it has the same receptor effects as the full hormone.

ACTH acts on melanocortin receptors, which are cell-surface proteins that respond to the hormone. A stability test does not show which receptors Semax acts on, whether it activates them, or how strongly.

Cell studies test effects in isolated cells, animal studies examine effects in animals, and human studies measure outcomes in people. These study types answer different questions, and none can be replaced by a test of peptide breakdown.

The Semax 10mg listing describes a synthetic seven-amino-acid peptide derived from ACTH(4 to 10), modified for stability, and marked for research use only. It fits this discussion because it names the same sequence form described above.

The linked research-use policy describes the product's stated research-use status. That label is separate from evidence about receptor action, safety, or approval.

Semax and N-acetyl Semax are different forms

Semax is described as modified for stability. It is distinct from changes made at the peptide's starting end.

N-acetyl Semax is a distinct form of the peptide.

N-acetyl Semax has an acetyl group attached to the peptide's N-terminal amino group. This changes the starting end, unlike Semax's C-terminal substitutions, and may alter recognition by aminopeptidases. The comparative blood and serum result above concerns Semax, so it does not establish N-acetyl Semax's stability without a matched test.

Researchers must test the specific form they want to describe, because a change at either end can affect how a peptide behaves.

Conclusion

Semax is described as a synthetic peptide based on an ACTH fragment and modified for stability. That description does not establish how it breaks down in the body, its receptor action, safety, or clinical benefit.